Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy-Reference-Cited by-同舟云学术

Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

Published:2018-04-26 Issue:10 Volume:24 Page:2272-2277
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Ramos Guilherme P¹,Stroh Gregory¹,Al-Bawardy Badr²,Faubion William A²,Papadakis Konstantinos A²,Escalante Patricio³

Affiliation:

1. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

2. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA

3. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic Center of Tuberculosis, Mayo Clinic, Rochester, Minnesota, USA

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/10/2272/25739039/izy133.pdf

Reference54 articles.

1. American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease;Terdiman;Gastroenterology,2013

2. Ulcerative colitis practice guidelines in adults: american college of gastroenterology, practice parameters committee;Kornbluth;Am J Gastroenterol,2010

3. Tuberculosis associated with therapy against tumor necrosis factor alpha;Winthrop;Arthritis Rheum,2005

4. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report;Gómez-Reino;Arthritis Rheum,2003

5. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in sweden;Askling;Arthritis Rheum,2005

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consenso para la gestión de riesgo en la prescripción de terapias biológicas o de antirreumáticos sintéticos con blanco dirigido: Asociación Colombiana de Reumatología 2023;Revista Colombiana de Reumatología;2024-04

2. Analysis of Risk Factors for Developing Tuberculosis in Patients Who Received Prophylactic Latent Tuberculosis Infection Treatment with Experience of Biologic Medications;Biological and Pharmaceutical Bulletin;2023-12-01

3. The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report;Medicine;2023-07-14

4. Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease;Saudi Journal of Gastroenterology;2022-11-21

5. Therapeutic effect of an anti-tuberculosis agent, isoniazid, and its nano-isoform in ulcerative colitis;International Immunopharmacology;2021-07